Novartis Investigative Site

Shizuoka 431-3192

0 studies enrolling now · 5 studies all time

What they study most

Breast Cancer, Cancer, Carcinoma, Renal Cell, Melanoma, Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia, Renal Cell Carcinoma (RCC)

Studies at this site

• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). — Completed
• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma — Completed
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
• Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. — Completed
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) — Completed